tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACLX Stock Latest News

Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment
Company AnnouncementsArcellx Advances Phase 3 Study for Multiple Myeloma Treatment
4d ago
ACLX
Arcellx initiated with a Buy at Citi
PremiumThe Fly
Arcellx initiated with a Buy at Citi
1M ago
ACLX
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
PremiumRatings
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
1M ago
ACLX
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
PremiumRatings
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
1M ago
ACLX
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
PremiumRatings
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
1M ago
ACLX
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating
PremiumRatingsPromising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating
1M ago
ACLX
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
Premium
Ratings
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
1M ago
ACLX
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy
Premium
Ratings
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy
1M ago
ACLX
Arcellx Inc Holds Annual Stockholders Meeting
PremiumCompany Announcements
Arcellx Inc Holds Annual Stockholders Meeting
2M ago
8K
ACLX
Arcellx, Inc. Reports Q1 2025 Financial Results
PremiumCompany Announcements
Arcellx, Inc. Reports Q1 2025 Financial Results
2M ago
ACLX
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst
PremiumRatings
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst
2M ago
ACLX
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating
PremiumRatings
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating
2M ago
ACLX
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy
PremiumRatingsPromising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy
2M ago
ACLX
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel
Premium
Ratings
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel
2M ago
ACLX
Arcellx Announces Positive Phase 2 Study Results
Premium
Company Announcements
Arcellx Announces Positive Phase 2 Study Results
2M ago
8K
ACLX
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
PremiumThe Fly
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
2M ago
ACLX
GILD
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating
PremiumRatings
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating
2M ago
ACLX
Arcellx price target lowered to $93 from $133 at Scotiabank
PremiumThe Fly
Arcellx price target lowered to $93 from $133 at Scotiabank
2M ago
ACLX
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements
PremiumRatings
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements
2M ago
ACLX
Arcellx Inc: Promising iMMagine-1 Trial and Strong Financial Outlook Reinforce Buy Rating
PremiumRatingsArcellx Inc: Promising iMMagine-1 Trial and Strong Financial Outlook Reinforce Buy Rating
2M ago
ACLX
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts
Premium
Ratings
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts
2M ago
ACLX
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating
Premium
Ratings
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating
2M ago
ACLX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >